RhumbLine Advisers’s Dyne Therapeutics DYN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.47M | Buy |
154,541
+20,914
| +16% | +$199K | ﹤0.01% | 2053 |
|
|
2025
Q1 | $1.4M | Buy |
133,627
+5,383
| +4% | +$56.3K | ﹤0.01% | 2007 |
|
|
2024
Q4 | $3.02M | Buy |
128,244
+3,734
| +3% | +$88K | ﹤0.01% | 1675 |
|
|
2024
Q3 | $4.47M | Buy |
124,510
+2,915
| +2% | +$105K | ﹤0.01% | 1485 |
|
|
2024
Q2 | $4.29M | Buy |
121,595
+23,266
| +24% | +$821K | ﹤0.01% | 1479 |
|
|
2024
Q1 | $2.79M | Buy |
98,329
+22,091
| +29% | +$627K | ﹤0.01% | 1735 |
|
|
2023
Q4 | $1.01M | Buy |
76,238
+5,667
| +8% | +$75.4K | ﹤0.01% | 2243 |
|
|
2023
Q3 | $632K | Buy |
70,571
+6,659
| +10% | +$59.7K | ﹤0.01% | 2471 |
|
|
2023
Q2 | $719K | Buy |
63,912
+12,732
| +25% | +$143K | ﹤0.01% | 2469 |
|
|
2023
Q1 | $590K | Buy |
51,180
+1,966
| +4% | +$22.7K | ﹤0.01% | 2372 |
|
|
2022
Q4 | $570K | Buy |
49,214
+396
| +0.8% | +$4.59K | ﹤0.01% | 2402 |
|
|
2022
Q3 | $620K | Buy |
48,818
+4,436
| +10% | +$56.3K | ﹤0.01% | 2401 |
|
|
2022
Q2 | $305K | Buy |
44,382
+6,938
| +19% | +$47.7K | ﹤0.01% | 2744 |
|
|
2022
Q1 | $361K | Sell |
37,444
-661
| -2% | -$6.37K | ﹤0.01% | 2572 |
|
|
2021
Q4 | $453K | Sell |
38,105
-285
| -0.7% | -$3.39K | ﹤0.01% | 2547 |
|
|
2021
Q3 | $623K | Buy |
38,390
+1,400
| +4% | +$22.7K | ﹤0.01% | 2439 |
|
|
2021
Q2 | $778K | Buy |
36,990
+25,442
| +220% | +$535K | ﹤0.01% | 2353 |
|
|
2021
Q1 | $179K | Buy |
+11,548
| New | +$179K | ﹤0.01% | 2858 |
|